











































Citation for published version:
Cameron, D 2009, 'Foundation clinical trials' Breast Cancer Research, vol 11 Suppl 3, pp. S23.,
10.1186/bcr2442
Digital Object Identifier (DOI):
10.1186/bcr2442
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




This is an Open Access article distributed under the terms of the
Creative Commons Attribution License which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Feb. 2015
Available online http://breast-cancer-research.com/supplements/11/S3/S23
Page 1 of 3
(page number not for citation purposes)
The present talk will address the following questions, posed
as part of the 2009 Breast Cancer Controversies Meeting:
Are clinical trials still essential to develop the new generation
of biological agents? Are the traditional large clinical trials
appropriate in developing drugs that may have a target in a
minority of breast cancers? Are clinical trials compatible with
the aim of individualising treatments?
The following answers to these questions are perhaps more
conservative than might have been expected: perhaps being
conservative in a controversies meeting might in itself be
seen as controversial.
The past 50 years of clinical medicine have seen a shift in the
evidence required to justify a treatment from being based on
experience, gleaned from intelligent analysis of anecdotes
and both retrospective and prospective clinical series, to that
where the aim is to have randomised clinical trials under-
pinning the rational for a particular therapeutic strategy. It is
therefore with trepidation that one even asks the question of
whether clinical trials are still essential, since it would seem to
challenge the work of many eminent physicians and
statisticians. But what is surely open to challenge is whether
in an era of much greater understanding of the biology of a
disease, and with the advent of agents that are only expected
to be active in subsets of patients, the traditional inclusive,
phase III design is still the best model to provide a robust
estimate of the effect of a novel intervention in the relevant
population of patients. Clinical trials are simply well-designed
clinical experiments to test a particular hypothesis: and most
anticipate a future in which the interaction between a
treatment and the biology of the disease is pivotal to the
hypothesis under scrutiny.
Furthermore, many founder clinical trials have changed
practise and outcomes for women with breast cancer. The
analysis of improvements in the population of British
Columbia breast cancer [1] or in French patients presenting
with metastatic disease [2], as well as indirect comparisons
between adjuvant chemotherapy trials (Barros C, personal
communication), all confirm that a series of well-designed
phase III trials in patient populations not selected for on the
basis of tumour biology (and only sometimes on the basis of
risk of relapse) have revolutionised the outcomes for women
with breast cancer.
It is evident, however, that none of our current armamentarium
of systemic treatments works in every patient with breast
cancer. Even hormonal therapy, long since demonstrated by
the Oxford meta-analyses of many large trials as saving the
lives of around 1 in 10 patients diagnosed with breast cancer,
does not work in all patients. An intriguing thought experiment
is therefore to consider how we might have re-designed
those founder clinical trials with our current knowledge.
Data published by Allred and colleagues demonstrate using
immunohistochemistry that patients whose breast cancers
have no, or very low levels of, oestrogen receptor (ER) have a
poorer outcome [3]. These data led to the US Food and Drug
Administration definition of ER-positive breast cancer being
anyone whose cancer has an Allred category score ≥3
(equivalent to at least 1% of cells staining moderately, or at
least 10% of cells with any degree of staining). These data,
together with Oxford overview data demonstrating no
evidence of benefit for the use of adjuvant tamoxifen in
women with cancers deemed to be ER-negative by a
different, biochemical assay, have led some to believe that all
patients with ER-positive breast cancers, as defined by the
US Food and Drug Administration, should have adjuvant
hormonal therapy. In contrast, there are many data confirming
there to be subgroups of patients who have very endocrine-
sensitive cancers, who in an age of targeted therapies would
seem to be the ideal subpopulation in which one would test
the benefit of adjuvant hormonal therapy.
Clues to the diagnostic for this sensitive subgroup can be
found in many studies. The likelihood of a breast cancer
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cancer or in metastatic disease, is greater in those patients
whose tumours have much higher levels of ER expression.
Furthermore, retrospective analyses of the Arimidex,
Tamoxifen Alone or in Combination trial in fact suggested that
those women whose cancers were ER-positive but
progesterone receptor (PgR)-negative had greater additional
benefits from the use of 5 years’ anastrazole in place of
tamoxifen, than their counterparts whose tumours had signifi-
cant levels of PgR. Other analyses in that same study,
however, as well as the Breast International Group 1-98 and
Tamoxifen and Exemestane Adjuvant Multicentre trials, do not
confirm this differential benefit – and rather suggest that ER-
positive cancers with either coexpression of HER2 or lack of
expression of PgR do worse with any endocrine agent, and
that the relative level of additional benefit for the use of an
aromatase inhibitor may be similar across all types of ER-
positive breast cancers.
So how would we now design an adjuvant trial with a control,
no-hormonal therapy arm? If we target the trial at those
patients with very hormone-sensitive disease (ER strongly
positive, PgR-positive and/or HER2-negative), we would
enrich the population for those patients with better outcomes,
greater relative benefit from the therapy and longer time to
recurrence. The trial would certainly be positive, but might
take many years to conclude benefit, and would provide data
to suggest that only these very endocrine-sensitive patients
should be thus treated. Amongst the patients with weakly
endocrine-sensitive tumours, however, there is not only better
outcome on adjuvant tamoxifen than patients with ER-
negative disease, but also evidence of additional benefit from
an aromatase inhibitor. It is therefore highly likely that patients
with these tumours also benefit from adjuvant hormonal
therapy, and indeed – given their overall higher risk of
relapse, and their earlier relapse, particularly amongst those
patients with greater competing risks of death – their benefits
may be similar to the patients with more sensitive tumours.
Perhaps we should therefore design our trial to include such
patients.
But as one broadens the inclusion criteria, one runs into
another problem of design of targeted therapies – how sure
can we be that our pathologists could accurately identify the
right target group at the time of patient inclusion? This raises
two key questions. How can we allow for the fact that we
cannot be sure a diagnostic threshold for entry to a trial of a
biological agent is optimal? Also, how can we accommodate
the likelihood that science will progress during the life of the
trial to the extent that we will have a better diagnostic – or at
least a better, optimised threshold for that entry diagnostic?
Let me illustrate with a simple example. Trastuzumab was
developed as an effective therapy for patients whose tumours
overexpress HER2. The efficacy of trastuzumab is certain: its
target population is now reasonably, but not perfectly,
defined. The pivotal registration trial H0648 allowed inclusion
of patients with either 2+ or 3+ staining by immuno-
histochemistry in a single central laboratory [4]. Of course,
we now know that this is not the precise group of patients
whom it is appropriate to treat with the drug, although we are
still a little unclear as to the best diagnostic, and have still to
deal with inevitable interlaboratory variations in results.
Furthermore, this key phase III trial in metastatic breast
cancer also allowed patients to be treated with either of two
chemotherapy regimens, depending on prior chemotherapy
exposure. The overall trial was clearly positive, but it was
really only the data from the 31% (145/469) of patients
treated with paclitaxel who had 3+ tumours that provided the
basis for subsequent licensing and clinical practise. Indeed,
these data were not included in the primary manuscript, only
in a later article [5]. These data were therefore in reality only
hypothesis-generating, and the confidence intervals were
inevitably broader than those in the primary paper.
Therefore, although the subsequent randomised trial of doce-
taxel with or without trastuzumab subsequently confirmed
that adding trastuzumab to a taxane in women with HER2 3+
tumours was beneficial, there was a not inconsiderable risk
that the benefit observed in the appropriate taxol-treated
group of the original phase III trial might have been much less
than what was reported – which could have led to a
considerable delay in access to a drug that revolutionised
therapy and outcomes for women with an aggressive form of
breast cancer. Next time, the clinical community might not be
so lucky in an unplanned subgroup analysis of the post-hoc-
defined appropriate subgroup of patients.
So how do we balance the desire to select only the appro-
priate target group of cancers with the need to be able to
later refine the diagnostic test and accommodate inter-
laboratory variations in assays? Perhaps the answer is that
we need to rethink the statistical designs. The concept that
the only valid conclusion from a trial comes from the primary
analysis of the intent-to-treat (ITT) population may have
served us well when post-hoc elimination of patients from the
analysis population was seen to risk introducing bias. We
risk, however, either increasing the chance of a false-negative
trial by sticking to the primary ITT analysis, simply because we
did not allow for scientific progress during the life of the trial
(as would have happened had we not known how to test,
even crudely, for trastuzumab sensitivity in the 1990s), or
underpowering the key analyses because the true sensitive
population has only poor overlap with those patients actually
enrolled.
Could we not consider trials with sufficient power to allow
two primary analyses? One analysis based on the original trial
population, and a second using a different diagnostic to be
applied post randomisation but just before the primary
analysis? In parallel with the parent, phase III practice-
changing trial, therefore, a programme of smaller, targeted
phase II and/or quality assurance studies designed to refine
the diagnostic test for sensitivity could be conducted. This
would perhaps be a better strategy than conducting a large
and expensive phase III trial with a higher risk of being
negative if the entry diagnostic was wrong, or delaying the
drug development until such point as the diagnostic was
better defined, costing not only money but also patient lives?
So I believe we still need phase III trials to develop new
agents in an era of stratified medicine.
How does this approach deliver individualised therapeutic
strategies? In simple terms, no prior trial can answer the
question as to the best therapy for a particular patient, since
each tumour/patient combination is essentially unique. Short
of studies that can sequentially test different therapies in one
patient [6], deductions need to be derived from studies in
selected populations that most closely match the patient in
the clinic. By designing future trials in selected patient groups
with spare power to render additional analyses more robust,
however, one might be able to allow data from an earlier era,
with different biomarker availability, to be re-analysed in the
light of new developments. The increasingly routine practise
of storing biological samples from patients in trials with full
consent for later analyses is an important way of securing the
ability to perform such analyses.
Clinical trials are with us for the foreseeable future. Their
design, however, will need to accommodate analyses of
interaction effects between biological variables and the
intervention under study, and will need to have the
appropriate statistical power to do this in the light of new
knowledge appearing during the lifetime of the trial.
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